| Number: 201209059 |
Principal Investigator: Wagner-Johnston, Nina |
| Title: Multisite randomized controlled trial of continuing vs. discontinuing statins |
| Description: The purpose of this study is to determine if discontinuing statin medications is safe and can reduce the burden of taking numerous medications. We anticipate that people with advanced illness will have less medicine-related side effects and symptoms if statins are discontinued, better quality of lif...MORE |
| ___________________________________________________________________________________________________ |
| Number: 201102254 |
Principal Investigator: Edmundowicz, Steven |
| Title: Endoscopic Resection or Ablation for Patients with Dysplasia or Intramucosal Cancer Requiring Treatment of Barrett’s Esophagus: the ERADICATE trial A Multi-Center Randomized Controlled Trial |
| Description: This is a multi-center prospective, RCT conducted at 4 centers. 82 patients with HGD and/or EC who meet the study criteria will be enrolled, undergo a baseline diagnostic EMR and then be randomized in a 1:1 ratio to undergo treatment by either stepwise endoscopic mucosal resection (S-EMR) or radiofr...MORE |
| ___________________________________________________________________________________________________ |
| Number: RTOG 1010 |
Principal Investigator: Robinson, Clifford |
| Title: A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of Her2-Overexpressing Esophageal Adenocarcinoma |
| Description: This study is being done to compare the effects, good and/or bad, of the addition of trastuzumab to standard chemotherapy, radiation, and surgery for patients with HER2 positive esophageal cancer....MORE |
| ___________________________________________________________________________________________________ |
| Number: CALGB 80803 |
Principal Investigator: Lockhart, A. Craig |
| Title: Randomized Phase II Trial of PET Scan-Directed Combined Modality Therapy in Esophageal Cancer |
| Description: The purpose of this trial is to learn if we can improve the outcomes for patients with esophageal cancer by using PET/CT scans to determine whether or not a particular chemotherapy regimen is showing any effect on the tumor. We are trying to learn if PET/CT response can be used as a way to better di...MORE |
| ___________________________________________________________________________________________________ |
| Number: 201212078 |
Principal Investigator: Lockhart, A. Craig |
| Title: Randomized, Open Label, Phase 2 Study of MM-111 and Paclitaxel with or without Trastuzumab in Patients with ‘Traditional’ and ‘Non-Traditional’ HER2 Expressing Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach Who Have Failed Front Line Metastatic or Locally Advanced Therapy |
| Description: The purpose of this study is to evaluate how well MM-111 controls esophageal, gastroesophageal, or gastric cancer that expresses a protein called HER2 when given in combination with standard treatment (paclitaxel and trastuzumab)....MORE |
| ___________________________________________________________________________________________________ |
| Number: 201204145 |
Principal Investigator: Matthews, Brent |
| Title: Photoacoustic Endoscopy of Barrett's Esophagus: A Pilot Study |
| ___________________________________________________________________________________________________ |
| Number: 201205189 |
Principal Investigator: Mullady, Daniel |
| Title: Predicting Stage and Severity of Esophageal Adenocarcinoma using a Dysphagia Symptom Questionnaire |
| ___________________________________________________________________________________________________ |
| Number: 201101765 |
Principal Investigator: Puri, Varun |
| Title: Prospective Collection of health Information and Biospecimens in Esophageal Cancer |
| ___________________________________________________________________________________________________ |
| Number: 201209045 |
Principal Investigator: Kushnir, Vladimir |
| Title: Outcomes following Endoscopic Therapy for Early Stage Esophageal Cancer |
| ___________________________________________________________________________________________________ |
| Number: 201108327 |
Principal Investigator: Wang-Gillam, Andrea |
| Title: Phase I Study of Erlotinib and Temsirolimus in Resistant Solid Malignancies |
| Description: The purpose of this study is to determine the maximum tolerated dose and side effects of the combination of two drugs, temsirolimus and erlotinib, used to treat solid tumor cancers. Temsirolimus is approved by the Food and Drug Administration (FDA) for treatment of renal cancer and is considered inv...MORE |
| ___________________________________________________________________________________________________ |
| Number: 201107068 |
Principal Investigator: Lockhart, A. Craig |
| Title: Phase I Safety and Pharmacokinetic Study of XRP6258 (Cabazitaxel) In Advanced Solid Tumor Patients with Varying Degrees of Hepatic Impairment |
| Description: The purpose of this study is to determine if Cabazitaxel is a safe treatment for patients with advanced cancers of different types who also have different levels of liver dysfunction. The highest safe dose of cabazitaxel (the maximum tolerated dose, or MTD) that can be given to patients with your le...MORE |
| ___________________________________________________________________________________________________ |
| Number: 201102468 |
Principal Investigator: Lockhart, A. Craig |
| Title: An Open-Label Study to Determine the Maximum Tolerated Dose of the PARP Inhibitor CEP-9722 When Administered as a Single Agent in Patients With
Advanced or Metastatic Solid Tumors |
| Description: There are two parts to this research study. The purpose of Part 1 is to find out the highest safe dose of the investigational drug CEP-9722. “Investigational” means that the study drug has not been approved by the United States Food & Drug Administration (F.D.A). Part 2 of the study is to find out m...MORE |
| ___________________________________________________________________________________________________ |
| Number: 201102462 |
Principal Investigator: Lockhart, A. Craig |
| Title: A Phase 1b, Multi-Center, Open Label, Uncontrolled, Serial Cohort, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Daily Oral Doses of ZSTK474 in Subjects with Advanced Solid Malignancies |
| Description: The main purpose of this study is to find out if the drug ZSTK474 is safe in people who have advanced cancers.
ZSTK474 is an investigational (experimental) drug. This means it has not been approved by the Food and Drug Administration (FDA). It is not currently on the market in any country. This stu...MORE |
| ___________________________________________________________________________________________________ |